Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. More Details
Adequate balance sheet with proven track record.
Share Price & News
How has Tianjin Chase Sun PharmaceuticalLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 300026 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 300026's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 300026 underperformed the CN Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: 300026 underperformed the CN Market which returned 25.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tianjin Chase Sun PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Tianjin Chase Sun PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 300026 (CN¥4.4) is trading above our estimate of fair value (CN¥1)
Significantly Below Fair Value: 300026 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 300026 is good value based on its PE Ratio (25.8x) compared to the CN Pharmaceuticals industry average (30.5x).
PE vs Market: 300026 is good value based on its PE Ratio (25.8x) compared to the CN market (35x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 300026's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 300026 is good value based on its PB Ratio (1.8x) compared to the CN Pharmaceuticals industry average (2.7x).
How is Tianjin Chase Sun PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianjin Chase Sun PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Tianjin Chase Sun PharmaceuticalLtd is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Tianjin Chase Sun PharmaceuticalLtd performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300026 has high quality earnings.
Growing Profit Margin: 300026's current net profit margins (7.9%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: 300026's earnings have declined by 13.8% per year over the past 5 years.
Accelerating Growth: 300026's earnings growth over the past year (82.9%) exceeds its 5-year average (-13.8% per year).
Earnings vs Industry: 300026 earnings growth over the past year (82.9%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: 300026's Return on Equity (6.4%) is considered low.
How is Tianjin Chase Sun PharmaceuticalLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 300026's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥2.2B).
Long Term Liabilities: 300026's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥451.7M).
Debt to Equity History and Analysis
Debt Level: 300026's debt to equity ratio (15.3%) is considered satisfactory.
Reducing Debt: 300026's debt to equity ratio has increased from 2.3% to 15.3% over the past 5 years.
Debt Coverage: 300026's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 300026 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Tianjin Chase Sun PharmaceuticalLtd current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 300026's dividend (1.14%) is higher than the bottom 25% of dividend payers in the CN market (0.4%).
High Dividend: 300026's dividend (1.14%) is low compared to the top 25% of dividend payers in the CN market (1.82%).
Stability and Growth of Payments
Stable Dividend: 300026's dividend payments have been volatile in the past 10 years.
Growing Dividend: 300026's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.3%), 300026's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dan Zheng (55 yo)
Ms. Dan Zheng serves as Director General & Vice Chairman at Tianjin Chase Sun Pharmaceutical Co.,Ltd. She served as Deputy General Manager and Secretary of The Board at Tianjin Chase Sun Pharmaceutical Co....
|Director General & Vice Chairman||no data||CN¥2.61m||0.088% |
|Deputy GM||no data||CN¥1.24m||0.088% |
|Chairman||no data||CN¥2.81m||3.43% |
|Director||no data||CN¥60.00k||no data|
|Independent Director||6.33yrs||CN¥120.00k||no data|
|Independent Director||1yr||no data||no data|
|Director||no data||CN¥449.20k||no data|
|Chairman of the Supervisory Board||1.75yrs||CN¥58.50k||no data|
|Independent Director||3.08yrs||CN¥120.00k||no data|
|Director||1yr||no data||no data|
|Independent Director||1yr||no data||no data|
Experienced Board: 300026's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tianjin Chase Sun Pharmaceutical Co.,Ltd's company bio, employee growth, exchange listings and data sources
- Name: Tianjin Chase Sun Pharmaceutical Co.,Ltd
- Ticker: 300026
- Exchange: SZSE
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥13.068b
- Shares outstanding: 3.00b
- Website: https://www.chasesun.cn
Number of Employees
- Tianjin Chase Sun Pharmaceutical Co.,Ltd
- No. 20, Quanfa Road
- Tianjin Wuqing Development Area
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|300026||SZSE (Shenzhen Stock Exchange)||Yes||Domestic Shares||CN||CNY||Oct 2009|
|300026||XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)||Yes||Domestic Shares||CN||CNY||Oct 2009|
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, m...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/18 09:11|
|End of Day Share Price||2021/01/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.